CME/CE INFORMATION
Rural Health Clinical Congress Fall 2024
Saturday, November 23, 2024 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT
HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:
Breathing Easier in Rural and Underserved Communities:
Evidence-Based Solutions for Improving COPD Care and Outcomes
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Nicola A. Hanania, MD, MS, FCCP
Professor of Medicine - Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief of Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital
Houston, TX
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-068-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Nicola A. Hanania, MD, MS, FCCP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, Sanofi, and Verona Pharma; speakers’ bureau member for Regeneron Pharmaceuticals, Inc. and Sanofi; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, and Sanofi.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Confronting Challenges in Moderate-to-Severe Asthma Management:
Optimizing Care Across All Ages in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Nicola A. Hanania, MD, MS, FCCP
Professor of Medicine - Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief of Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital
Houston, TX
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Pharmacotherapy credit for Advanced Practice Registered Nurses to be determined.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-070-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Nicola A. Hanania, MD, MS, FCCP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, Sanofi, and Verona Pharma; speakers’ bureau member for Regeneron Pharmaceuticals, Inc. and Sanofi; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, and Sanofi.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Chronic Rhinosinusitis With Nasal Polyps Across the Continuum of Care:
A Collaborative Approach to Improving Outcomes in Rural and Underserved Settings
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Stella E. Lee, MD
Section Chief, Rhinology
Director, Brigham Sinus Center
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-071-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Stella E. Lee, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., Genzyme, GSK, Lyra Therapeutics, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals, Inc.; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., Genzyme, GSK, Lyra Therapeutics, Novartis Pharmaceuticals Corporation, OptiNose, Inc., and Sanofi and Regeneron Pharmaceuticals, Inc.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Advancing Early Detection and Treatment of Alzheimer’s Disease
in Rural and Underserved Communities: A Collaborative Approach
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Eisai, Inc.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Gary W. Small, MD
Chair of Psychiatry, Hackensack University Medical Center
Vice President, Behavioral Health Physician-in-Chief
H. Hovnanian Family Foundation Chair
Hackensack Meridian Health
Professor and Chair of Psychiatry & Behavioral Health
Hackensack Meridian School of Medicine
Hackensack, NJ
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-072-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Gary W. Small, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Acadia Pharmaceutics, Inc., Allergan, Inc. (now AbbVie, Inc.), Biogen, Inc., Cogensus AI, Inc., Electro Cellular Healthcare Solutions, LLC, Handok, Inc., Lundbeck, Inc., Eli Lilly and Company, McCormick Science Institute, Merry Life Biomedical Company, Ltd., Otsuka America Pharmaceutical, Inc. (previously Avanir Pharmaceuticals, Inc.), R. Hoffman-La Roche, Ltd., and Theravalues.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Envisioning Equity: Enhancing Access and Early Intervention for Retinal Disease
in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Yasha S. Modi, MD
Associate Professor of Ophthalmology
NYU Grossman School of Medicine
Director, Tele-Retina
New York, NY
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-059-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Yasha S. Modi, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Alcon, Inc., Alimera Sciences, Inc., Astellas Pharma, Inc., Dutch Ophthalmic Research Center, EyePoint Pharmaceuticals, Genentech, Inc., Neurotech Pharmaceuticals, Inc., Topcon Healthcare, Inc., Regeneron Pharmaceuticals, Inc., and ZEISS Group.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Moderate-to-Severe Atopic Dermatitis: A Primary Care Approach
to Improving Equitable Access to Care in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.
This session is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.
CREDIT AVAILABLE
All other healthcare professionals completing this activity will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
FACULTY
Benjamin N. Ungar, MD
Assistant Professor of Dermatology
Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Icahn School of Medicine at Mount Sinai
New York, NY
Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-069-L01-P)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Benjamin N. Ungar, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Bristol Myers Squibb, Fresenius Kabi, Galderma, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., Primus Pharmaceuticals, Inc., Sanofi, and UCB; contracted research for Bristol Myers Squibb, Incyte Corporation, RAPT Therapeutics, Inc., Pfizer, Inc., and Sanofi.
Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
FEE INFORMATION
There is no fee for this educational activity.
COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.